Search Medical Condition
Please enter condition
Please choose location from dropdown

Toyonaka-city, Japan Clinical Trials

A listing of Toyonaka-city, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (325) clinical trials

A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma

The purpose of this study is to determine whether the combination of nivolumab and ipilimumab is safe and effective for delaying or preventing recurrence of cancer in patients who have experienced the partial or entire removal of a kidney

Phase

4.09 miles

Learn More »

A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

The main purpose of this study is to compare how long subjects with esophageal cancer live overall or live without disease progression after receiving nivolumab and ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin

Phase

4.09 miles

Learn More »

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion (Cadenza Study)

The purpose of Part A is to determine whether sutimlimab administration results in a greater than or equal to (>=)1.5 gram per deciliter (g/dL) increase in hemoglobin (Hgb) level and avoidance of transfusion in participants with primary cold agglutinin disease (CAD) without a recent history of blood transfusion. The purpose ...

Phase

4.09 miles

Learn More »

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

Part 1 is an open-label, non-randomized, safety and PK run-in study designed to confirm the starting dose of talazoparib in combination with enzalutamide through assessment of target safety events and PK at select sites. Part 2 is a randomized, double-blind, placebo-controlled, multinational study comparing talazoparib plus enzalutamide vs. placebo plus ...

Phase

4.09 miles

Learn More »

Predictors Of Successful Extubation in Critically Ill Patients: Multicentre Observational Study

Primary Outcome Measures: Reintubation within 48 hours after extubation (logistic regression will be used to assess the risk factors) Secondary Outcome Measures: Use of non-invasive positive pressure ventilation or nasal high flow within 48 hours after extubation. Risk factors for extubation failure, with quantitative variables expressed as means (standard deviation) ...

Phase N/A

4.09 miles

Learn More »

Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma Phase III

Glioblastoma (GBM), the most frequent malignant primary brain tumor, has yet been incurable despite recent progress on its standard of care using TMZ as the main trunk of initial therapy in the newly diagnosed setting. One of the main reasons accounting for the dismal prognosis would attribute to lack of ...

Phase

4.09 miles

Learn More »

A Study of Nivolumab Nivolumab Plus Ipilimumab or Investigator's Choice Chemotherapy for the Treatment of Patients With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in patients with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic ...

Phase

4.09 miles

Learn More »

A Study Evaluating Safety and Tolerability and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Asian Adult Participants With Myeloproliferative Neoplasm

There are 2 parts to this study for which the primary objectives are to evaluate safety and tolerability, including dose-limiting toxicities (DLTs), and pharmacokinetics of navitoclax when administered alone (Part 1) or when administered in combination with ruxolitinib (Part 2). In Part 2, participants must have been receiving a stable ...

Phase

4.09 miles

Learn More »

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

Hepatitis B virus (HBV) is a small deoxyribonucleic acid virus that specifically infects the human liver. The acute phase of infection is either followed by an immune controlled state or progresses to chronic hepatitis B. The worldwide estimated prevalence of chronic HBV infection is about 292 million people affected. Hepatitis ...

Phase

4.09 miles

Learn More »

Stress Management Therapy for Meniere's Disease

BACKGROUND For the pathogenesis of inner ear hydrops resulting in Meniere's attacks, plasma vasopressin elevation due to stress and V2 receptor overexpression in the inner ear could be essential as a basis of this disease. In the present study, we'd like to find the effective and feasible way to reduce ...

Phase N/A

4.09 miles

Learn More »